Sign In
Buy AGTC
$0.397
+0 (+0%)
At Close: Feb 28, 2023
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
07:00am, Thursday, 04'th Feb 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-ass
AGTC Announces Pricing of Public Offering of Common Stock and Warrants
08:07am, Thursday, 28'th Jan 2021
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-as
AGTC Announces Proposed Public Offering of Common Stock and Warrants
04:35pm, Wednesday, 27'th Jan 2021
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-as
AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
04:19pm, Wednesday, 27'th Jan 2021
-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints- -Company plans longer
AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference
04:01pm, Wednesday, 06'th Jan 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020
04:05pm, Monday, 16'th Nov 2020
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-ass
AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa
07:00am, Wednesday, 11'th Nov 2020
- Durable improvements observed in visual sensitivity and visual acuity over a wide dose-range with a favorable safety profile -
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-ass
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2020 Results - Earnings Call Transcript
02:38pm, Wednesday, 09'th Sep 2020
Applied Genetic Technologies Corporation (NASDAQ:AGTC) Q4 2020 Earnings Conference Call September 9, 2020 8:00 A.M.
Applied Genetic Technologies Corporation 2020 Q4 - Results - Earnings Call Presentation
08:21am, Wednesday, 09'th Sep 2020
The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with their 2020 Q4 earnings call.
Applied Genetic Technologies (AGTC) Presents At Wedbush Pacgrow Healthcare Virtual Conference - Slideshow
06:09pm, Thursday, 13'th Aug 2020
The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with this event.
AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies
11:00am, Wednesday, 12'th Aug 2020
Patient Advisory Council to include advocates from the inherited retinal diseases global community New Patient Advisory Council to focus initially on Company’s clinical stage programs for X-linke
AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020
11:00am, Tuesday, 04'th Aug 2020
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-ass
Applied Genetic Technologies (AGTC) Receives a Rating Update from a Top Analyst - Markets
02:55pm, Wednesday, 22'nd Jul 2020
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Applied Genetic Technologies (AGTC – Research Report) today and set
FDA feedback allows for forward program development Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical developmentGAI
